A randomized, double-blind study to assess the efficacy and safety of prophylactic use of maribavir [Camvia] versus oral ganciclovir for the prevention of cytomegalovirus disease in recipients of orthotopic liver transplants.

Trial Profile

A randomized, double-blind study to assess the efficacy and safety of prophylactic use of maribavir [Camvia] versus oral ganciclovir for the prevention of cytomegalovirus disease in recipients of orthotopic liver transplants.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2015

At a glance

  • Drugs Maribavir (Primary) ; Ganciclovir
  • Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Shire; ViroPharma Incorporated
  • Most Recent Events

    • 13 Feb 2009 Status changed from active, no longer recruiting to discontinued, as reported in a ViroPharma media release..
    • 13 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top